SK bioscience, a leading South Korean vaccine and biotech company, has invested $3 million in FinaBio, a US-based biotech specializing in next-generation conjugate vaccine technology. This strategic investment will allow SK bioscience to enhance the immunogenicity and productivity of its existing conjugate vaccines, including those for pneumonia and typhoid. The collaboration will also accelerate SK bioscience’s global expansion plans.